Structure Therapeutics (NASDAQ: GPCR) experienced a remarkable 102% surge in its share price this past week, following the announcement of positive mid-stage clinical data for its oral glucagon-like peptide 1 (GLP-1) receptor agonist, aleniglipron. This data, derived from the Phase II ACCESS clinical program, demonstrated significant weight loss in participants with obesity and weight-related co-morbidities, capturing the attention of investors and analysts alike.
The implications of this data are substantial, particularly as Structure enters a competitive landscape dominated by giants like Eli Lilly (NYSE: LLY) and Novo Nordisk (Nasdaq Copenhagen: NOVO-B), both of which are advancing their own oral GLP-1 candidates. Analysts are now projecting aleniglipron could achieve peak sales of up to $6 billion, with some estimates even higher, indicating a robust market opportunity. As Structure plans to advance its Phase III trials, the excitement surrounding its candidate may position it as a serious contender in the obesity treatment market.
Get started today with Solo access →
